Belgium's iStar Medical SA is a step closer to getting European approval for MINIject after the company's second-generation micro-invasive glaucoma surgery (MIGS) device met expectations in its first-in-human study.
The Wavre-based company reported the six-month follow-up data from the 25-patient multi-center international trial on May 16. The study found no serious ocular adverse events associated with...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?